Canakinumab has been considered the preferred treatment option due to its longer half-life of 26 days (as compared to anakinra) [70] and has been shown to reduce the incidence of other inflammatory NLRP3-­related diseases, including pustular psoriasis and rheumatoid arthritis [71]. This evidence concerns the gene NLRP3 and rheumatoid arthritis.